Lucentis for pseudophakic CMO
1 October 2015
| Saruban Pasu
|
Retina / Uvea / Vitreous
|
Cataract, Irvine-Gass syndrome, cystoid macular edema, phacoemulsification, ranibizumab
Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...
